Nexalin Technology Inc. (NXL): Price and Financial Metrics
NXL Price/Volume Stats
| Current price | $0.89 | 52-week high | $3.23 |
| Prev. close | $0.92 | 52-week low | $0.65 |
| Day low | $0.84 | Volume | 8,731 |
| Day high | $0.90 | Avg. volume | 46,921 |
| 50-day MA | $0.83 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 6.48M |
NXL Stock Price Chart Interactive Chart >
Latest NXL News From Around the Web
Below are the latest news stories about NEXALIN TECHNOLOGY INC that investors may wish to consider to help them evaluate NXL as an investment opportunity.
Nexalin Technology Full Year 2022 Earnings: US$0.30 loss per share (vs US$1.43 loss in FY 2021)Nexalin Technology ( NASDAQ:NXL ) Full Year 2022 Results Key Financial Results Revenue: US$1.32m (up by US$1.18m from... |
Nexalin Technology Provides 2022 Year-End Business UpdateHOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022. Mark White, CEO of Nexalin Technology stated, “Nexalin has made significant progress towards commencing clinical trials of our Gen-2 and Gen-3 neurostimulation devices in the United States. Nexalin’s enhanced neurostimulation devices combine innovation, frequencies and algorithms to provide an unprecedented s |
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and RegulatoryHOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory. Mr. Nketiah is an expert in regulatory affairs, as well as clinical and quality assurance, specializing in US FDA and international regulatory approvals, with over 23 years of experience working directly with the FDA in the medical device and life sciences industries, |
Nexalin Technology CEO Provides Letter to ShareholdersHOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the following business update and letter to shareholders from its Chief Executive Officer, Mark White: To our valued shareholders, I would like to thank all of you for your tremendous support, as we look towards a very bright future in 2023 and beyond. Nexalin has built a solid foundation, grounded in strong intellectual property, and backed by growing clinical da |
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety DisorderThe Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep Treatment effect persisted after four months of follow-up HOUSTON, TX, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a white paper, titled, “A case report of Nexalin ADI in the treatment of somatic symptoms of anxiety, |
NXL Price Returns
| 1-mo | 5.99% |
| 3-mo | -10.09% |
| 6-mo | -59.73% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 18.83% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...